4. High risk AML and MDS patients will be included. Cohort 1: Morphological relapse after stem cell transplant: 1. MDS patients: Re-appearance of dysplastic changes in the bone marrow, with or without increase in bone marrow last count, which is pathologically consistent with myelodysplastic syndrome. 2. AML patients: Bone marrow blast count >/= 5%.